The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
Competing awards, new and renewals, since FY2014, under this notice and the notices it replaced.
- Past awards
- 14
- 14 new
- Median first-year cost
- $238,561
- $3,556,976 in all
- Institutions
- 14
- 14 contact PIs
- Patents
- 4
- from 3 funded projects
Awards by fiscal year
0
0
0
0
14
0
0
0
0
0
0
0
0
14151617181920212223242526
Fiscal years 2014 to 2026.
Most frequent institutions
- BATTELLE PACIFIC NORTHWEST LABORATORIES1
- ELECTRONIC BIOSCIENCES, INC.1
- FRED HUTCHINSON CANCER RESEARCH CENTER1
- GEORGIA INSTITUTE OF TECHNOLOGY1
- H. LEE MOFFITT CANCER CTR & RES INST1
and 9 other institutions
Most frequent study sections
- Special Emphasis Panel (ZCA1 TCRB-W (O1))8
- Special Emphasis Panel (ZCA1 TCRB-W (M1))4
- Special Emphasis Panel (ZCA1 SRB-X (J1))2
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| FY2018 | Glyco-typer: an antibody capture glycan imaging methodology1R21CA225474-01 | Haab, Brian B.Mehta, Anand S. | MEDICAL UNIVERSITY OF SOUTH CAROLINA, SC | First-year cost $339,424 | Study section ZCA1 |
| FY2018 | Microsatellite Sequencing to Enable Cancer Genotyping1R21CA228948-01 | Schibel, Anna | ELECTRONIC BIOSCIENCES, INC., CA | First-year cost $323,317 | Study section ZCA1 |
| FY2018 | Precision controllers of mammalian gene expression1R21CA223901-01 | Brent, Roger | FRED HUTCHINSON CANCER RESEARCH CENTER, WA | First-year cost $308,000 | Study section ZCA1 |
| FY2018 | Advancing Cancer Biology, Diagnostics and Therapeutics Outside of the Patient: Creation of a Novel, Autologous, Ex Vivo, Vascularized Model of the Tumor Microenvironment1R21CA223836-01 | Fields, Ryan C | WASHINGTON UNIVERSITY, MO | First-year cost $305,000 | Study section ZCA1 |
| FY2018 | An ultrasensitive targeted mass spectrometry system for proteomics analysis of single cells1R21CA223715-01 | Shi, Tujin | BATTELLE PACIFIC NORTHWEST LABORATORIES, WA | First-year cost $263,953 | Study section ZCA1 |
| FY2018 | Autohistomagnetic Isolation of Tumor-reactive T-cells1R21CA214285-01A1 | Mailloux, Adam William | H. LEE MOFFITT CANCER CTR & RES INST, FL | First-year cost $257,382 | Study section ZCA1 |
| FY2018 | Development of Catch and Release Approach for Multi-Drug Local Delivery of Chemotherapies1R21CA228997-01 | Royzen, Maksim | STATE UNIVERSITY OF NEW YORK AT ALBANY, NY | First-year cost $249,456 | Study section ZCA1 |
| FY2018 | Discovering hybrid inhibitors for tumor microenvironment disruption1R21CA214239-01A1 | Van Deventer, James Allen | TUFTS UNIVERSITY MEDFORD, MA | First-year cost $227,666 | Study section ZCA1 |
| FY2018 | A microreactor chip platform for quantitative analysis of unsaturated aldehydes in exhaled breath1R21CA229057-01 | Fu, Xiao-An | UNIVERSITY OF LOUISVILLE, KY | First-year cost $226,587 | Study section ZCA1 |
| FY2018 | Novel NeuCode Tagging Reagents for Identification and Quantification of Intact Proteoforms in Cancer Tissues1R21CA223887-01 | Smith, Lloyd M | UNIVERSITY OF WISCONSIN-MADISON, WI | First-year cost $226,320 | Study section ZCA1 |
| FY2018 | Novel platform linking cancer-specific glycosylation with cell signaling outcomes1R21CA229044-01 | Abbott, Karen L. | UNIV OF ARKANSAS FOR MED SCIS, AR | First-year cost $225,250 | Study section ZCA1 |
| FY2018 | Optogenetic tools for the dissection of oncogenic signaling mediated by kinases1R21CA223915-01 | Karginov, Andrei VRehman, Jalees | UNIVERSITY OF ILLINOIS AT CHICAGO, IL | First-year cost $219,463 | Study section ZCA1 |
| FY2018 | Developing Adhesome Technology as a Physical Marker of Highly Metastatic Cells1R21CA217735-01A1 | Engler, Adam J | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | First-year cost $196,041 | Study section ZCA1 |
| FY2018 | Stimulated Raman scattering spectroscopic optical coherence tomography (SRS-SOCT) for label-free molecular imaging of brain tumor pathology1R21CA223853-01 | Robles, Francisco E | GEORGIA INSTITUTE OF TECHNOLOGY, GA | First-year cost $189,117 | Study section ZCA1 |
Newest fiscal year first, then first-year cost.
Patents from its funded projects
4 patents name 3 of the 14 funded projects.
- US 12,296,017 (opens the patent at USPTO, a PDF, in a new tab)BIOORTHOGONAL COMPOSITIONSGranted May 13, 2025 to Tambo, Inc.R21CA228997 · STATE UNIVERSITY OF NEW YORK AT ALBANY, NY
- US 12,187,992 (opens the patent at USPTO, a PDF, in a new tab)METHOD AND DEVICE FOR EARLY CANCER SCREENINGGranted January 7, 2025 to THE REGENTS OF THE UNIVERSITY OF CALIFORNIAR21CA217735 · UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA
- US 11,965,002 (opens the patent at USPTO, a PDF, in a new tab)OPTOGENETIC CONSTRUCT FOR ALLOSTERIC CONTROL OF PROTEIN ACTIVITYGranted April 23, 2024 to THE BD OF TRUSTEES OF THE UNIVERSITY OF ILLINOISR21CA223915 · UNIVERSITY OF ILLINOIS AT CHICAGO, IL
- US 11,253,600 (opens the patent at USPTO, a PDF, in a new tab)Bioorthogonal CompositionsGranted February 22, 2022 to Tambo, Inc. and The Research Foundation for the State University of New YorkR21CA228997 · STATE UNIVERSITY OF NEW YORK AT ALBANY, NY
Each number opens the patent at USPTO, beside the project NIH ties it to and that project's institution. NIH ties a patent to a project, not to a year of its funding, and says its list is incomplete. The grant date and the owners are USPTO's: the organizations the patent names as assignees on the day it was granted. Source: United States Patent and Trademark Office, www.uspto.gov, which does not endorse ScienceDex.
Data: Grants.gov's daily extract and NIH's notice pages, award files and patents file, in ScienceGraph release conductgrants-2026-11-12-0.3.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.